pharmaphorum

MARCH 7, 2022

A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including the Boehringer Ingelheim Venture Fund. The Princeton, New Jersey-based startup will use the funding to develop its artificial intelligence and imaging based drug discovery platform, used to identify compounds with new and under-exploited mechanisms of action.

Compounding 134

Compounding 134

Pharma Mirror

MARCH 7, 2022

With the recent pandemic lingering on, and the new devastating news of a potential global war, prioritizing your overall health and well-being has never been more critical. While the covid19 pandemic showed us just how important physical health and a robust immune system are, the news of the war is quickly showing us the importance of mental well-being.

Immunization 52

Immunization 52

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . Vaccines are a powerful tool and crucial part of fighting diseases, such as tetanus, measles, meningitis, and, recently, COVID-19.

Vaccines 98

Vaccines 98

Outsourcing Pharma

MARCH 7, 2022

The two companies, along with Datavant, will combine real-world data and decentralized platforms to yield better patient information management and insights.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 7, 2022

Young entrepreneurs launch healthcare communications company Collected Group to tackle unmet needs in healthcare professional engagement. Collected Group will offer scientific and strategic services focused on an innovative approach called omniverse communication to drive improvement in people health. London, 7 th March, 2022 – Healthcare communication entrepreneurs, Emily Harrison, and Mohammed Saleh Bham have launched Collected Group, a healthcare communication company aimed at helping b

Communication 90

Communication 90

Outsourcing Pharma

MARCH 7, 2022

The business tech companyâs Pharmaceutical Supply Chain Vision Study gauges pharma and patient perceptions, including key concerns and areas for improvement.

52

52

Pharma Times

MARCH 7, 2022

Fully-automated molecular system with small footprint provides greater flexibility for laboratories without much space

46

46

pharmaphorum

MARCH 7, 2022

Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance has become the first drug in the class to be approved in the EU for all adults with symptomatic chronic heart failure (CHF), giving the drug an edge in its battle for market share with AstraZeneca’s rival Forxiga. The European Commission has expanded the label for Jardiance (empagliflozin) to include heart failure with preserved ejection fraction (HFpEF), in addition to its earlier indication in heart failure with reduced

Labelling 52

Labelling FDA 52

Pharma Times

MARCH 7, 2022

Largest unmet need in cardiovascular medicine finally receives approved therapy

46

46

pharmaphorum

MARCH 7, 2022

Bristol-Myers Squibb’s Opdivo has been playing second fiddle to Merck & Co’s Keytruda in the non-small cell lung cancer (NSCLC) market for years, but now it has a chance to take the limelight on its own. Opdivo (nivolumab) has become the first and only cancer immunotherapy to be approved in the US for the neoadjuvant treatment of NSCLC, given to shrink tumours before they are removed using surgery.

Chemotherapy 52

Chemotherapy FDA 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

MARCH 7, 2022

The former chair of NHS Digital has slammed the decision to absorb the unit into NHS England as a “significant retrograde step” that could undermine citizens’ rights over their health data. In a letter to the BMJ, Kingsley Manning – who headed NHS Digital between 2013 and 2016 – said that the move is a “grave error” that could threaten the confidentiality and use of patient data.

Documentation 95

Documentation 95